Organization

IRCCS Istituto Romagnolo per lo Studio dei Tumori

2 abstracts

1 poster

Poster

Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies

Abstract

Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis.

Org: Gregorio Marañón University General Hospital, IRCCS Istituto Romagnolo per lo Studio dei Tumori, Institute of Oncology Ljubljana, Roche Products Limited, Roche,

Abstract

Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.

Org: EO Ospedali Galliera, University Hospital Munich, International Breast Cancer Center (IBCC), Vall d'Hebron Institute of Oncology, Maggiore della Carità University Hospital,